The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 24: 3515 - 3520

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.24.013

Drugs and Clinic Practice

Effects of semaglutide on prognosis in patients with diabetes mellitus complicated with unstable angina after percutaneous coronary intervention

  • Ziming ZHAO ,
  • Qi MA ,
  • Jian CHEN ,
  • Yuan CHEN ,
  • Liuyi CUI ,
  • Yujie. ZHAO
Expand
  • Department of Cardiology，He′nan Cardiovascular Hospital Affiliated to Southern Medical University，Zhengzhou Cardiovascular Hospital，Zhengzhou 450000，He′nan，China

Received date: 2024-05-16

  Online published: 2024-12-23

Fold

Abstract

Objective To investigate the effect of semaglutide on the prognosis in patients with unstable angina complicated with diabetes after percutaneous coronary intervention. Methods A total of 178 patients with unstable angina complicated with diabetes diagnosed in Zhengzhou Cardiovascular Hospital from September 1， 2022 to March 31， 2023 were included. The patients were divided into a study group （43 patients） and a control group （135 patients） according to whether they received semiglutide or not. Changes in HbA1c， fasting blood glucose， body weight， blood pressure and blood lipid were observed before and after treatment. Baseline data and differences in postoperative adverse cardiovascular events including cardiovascular death， all-cause death， acute myocardial infarction， acute ischemic stroke， re-hospitalization due to unstable angina， and coronary revascularization were compared between the two groups. Results After 12 weeks of treatment， fasting blood-glucose levels in the study group and the control group were （6.0 ± 0.9）， （8.5 ± 1.3） mmol/L， HbA1c levels were （6.5 ± 0.7）%， （7.9 ± 0.5）%， BMI was （22. 8 ± 3.0）， （25.0 ± 2.4） kg/m2， systolic blood pressure was （135.3 ± 9.7）， （141.5 ± 8.3） mmHg， respectively， with significant differences （P < 0.05 for all comparisons）. Diastolic blood pressure showed a trend of improvement （84.7 ± 7.7）， （86.6 ± 7.7）mmHg， but there was no statistical difference. Conclusions For patients with unstable angina complicated with diabetes after percutaneous coronary intervention， the application of semaglutide can effectively control blood glucose， body weight， systolic blood pressure， and reduce the risk of cardiovascular events.

Key words： semaglutide; unstable angina; type 2 diabetes; percutaneous coronary intervention; prognosis

Cite this article

Ziming ZHAO , Qi MA , Jian CHEN , Yuan CHEN , Liuyi CUI , Yujie. ZHAO . Effects of semaglutide on prognosis in patients with diabetes mellitus complicated with unstable angina after percutaneous coronary intervention[J]. The Journal of Practical Medicine, 2024 , 40(24) : 3515 -3520 . DOI: 10.3969/j.issn.1006-5725.2024.24.013

References

1 ARNETT D K， BLUMENTHAL R S， ALBERT M A， et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease： a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines［J］. Circulation， 2019， 140（11）： e596-e646. doi:10.1161/cir.0000000000000725
2 OMIDI N， SADEGHIAN S， SALARIFAR M，et al. Relationship between the severity of coronary artery disease and cardiovascular risk factors in acute coronary syndrome： based on tehran heart center's data registry［J］. J Tehran Heart Cent，2020， 15（4）：165-170.
3 SIA C H， KO J， ZHENG H， et al. Comparison of mortality outcomes in acute myocardial infarction patients with or without standard modifiable cardiovascular risk factors［J］. Front Cardiovasc Med，2022，9：876465. doi:10.3389/fcvm.2022.876465
4 FLORA G D， NAYAK M K. A brief review of cardiovascular diseases， associated risk factors and current treatment regimes［J］. Curr Pharm Des， 2019， 25（38）： 4063-4084. doi:10.2174/1381612825666190925163827
5 VANASSCHE T， VERHAMME P， ANAND S S， et al. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease： an analysis of the randomized， double-blind COMPASS trial［J］. Eur J Prev Cardiol， 2020， 27（3）： 296-307. doi:10.1177/2047487319882154
6 纪立农. 胰高血糖素样肽1受体激动剂周制剂中国证据与专家指导建议［J］. 中国糖尿病杂志， 2022， 30（6）：405-411.
7 YANG W， CHEN L， JI Q，et al. Liraglutide provides similar glycaemic control as glimepiride （both in combination with metformin） and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China， South Korea and India： a 16-week， randomized， double-blind， active control trial［J］. Diabetes Obes Metab， 2011，13（1）：81-88. doi:10.1111/j.1463-1326.2010.01323.x
8 HTIKE Z Z， ZACCARDI F， PAPAMARGARITIS D， et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes： a systematic review and mixed-treatment comparison analysis［J］. Diabetes Obes Metab， 2017，19（4）：524-536. doi:10.1111/dom.12849
9 BYRNE R A， ROSSELLO X， COUGHLAN J J， et al. 2023 ESC Guidelines for the management of acute coronary syndromes［J］. Eur Heart J， 2023， 44（38）：3720-3826.
10 MARX N， FEDERICI M， SCHUTT K，et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes［J］. Eur Heart J，2023，44（39）：4043-4140.
11 段纬喆，王中京. 德谷胰岛素联合利拉鲁肽在血糖控制不佳的2型糖尿病患者中的应用［J］. 实用医学杂志， 2023， 39（2）：175-179.
12 DEFRONZO R A. From the Triumvirate to the ominous octet： a new paradigm for the treatment of type 2 diabetes mellitus［J］. Diabetes， 2009， 58（4）：773-773. doi:10.2337/db09-9028
13 AHMANN A J， CAPEHORN M， CHARPENTIER G，et al. Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes （SUSTAIN 3）： a 56-week， open-label， randomized clinical trial［J］. Diabetes Care， 2018，41（2）：258-266. doi:10.2337/dc17-0417
14 SHI L X， LIU X M， SHI Y Q，et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes： Post-hoc analyses of a randomized， double-blind， phase Ⅲ study［J］. J Diabetes Investig， 2020，11（1）：142-150. doi:10.1111/jdi.13075
15 WANG W， NEVAREZ L， FILIPPOVA E， et al. Efficacy and safety of once?weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea： a 52?week open?label， randomized phase Ⅲ trial［J］. Diabetes Obes Metab， 2019， 21（2）：234?243. doi:10.1111/dom.13506
16 XIAO X， WANG C， LAI X， et al. Achieving the composite end?point of glycated hemoglobin<7.0% without weight gain or hypoglycemia with once?weekly dulaglutide in Chinese patients with type 2 diabetes： a post?hoc analysis［J］. J Diabetes Investig， 2020， 11（3）： 647?652. doi:10.1111/jdi.13187
17 DIAMANT M， VAN GAAL L， STRANKS S， et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes （DURATION?3）： an open?label randomised trial［J］. Lancet， 2010， 375（9733）：2234?2243. doi:10.1016/s0140-6736(10)60406-0
18 SINGH S， WRIGHT E E， KWAN A Y， et al. Glucagon?like peptide?1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus： a systematic review and meta?analysis［J］. Diabetes Obes Metab， 2017，19（2）：228?238. doi:10.1111/dom.12805
19 MADSBAD S. Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists［J］. Diabetes Obes Metab， 2016， 18（4）：317-322. doi:10.1111/dom.12596
20 双丹丹，张惠莉. 司美格鲁肽治疗成人非2型糖尿病超重和肥胖患者效果的Meta分析［J］. 实用医学杂志， 2023， 39（3）：343-349.
21 AHREN B， ATKIN S L， CHARPENTIER G，et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials［J］. Diabetes Obes Metab， 2018，20（9）：2210-2219. doi:10.1111/dom.13353
22 BLUNDELL J， FINLAYSON G， AXELSEN M， et al. Effects of once-weekly semaglutide on appetite， energy intake， control of eating， food preference and body weight in subjects with obesity［J］. Diabetes Obes Metab， 2017，19（9）：1242-1251. doi:10.1111/dom.12932
23 CHRISTOU G A， KATSIKI N， BLUNDELL J， et al. Semaglutide as a promising antiobesity drug［J］. Obes Rev， 2019，20（6）：805-815. doi:10.1111/obr.12839
24 MARSO S P， BAIN S C， CONSOLI A， et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes［J］. N Engl J Med， 2016，375（19）：1834-1844. doi:10.1056/nejmoa1607141
25 KRISTENSEN S L， RORTH R， JHUND P S， et al. Cardiovascular， mortality， and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes： a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol［J］. Lancet Diabetes Endocrinol， 2019，7（10）：776-785. doi:10.1016/s2213-8587(19)30249-9
26 ZANG L， LIU Y， GENG J， et al. Efficacy and safety of liraglutide versus sitagliptin， both in combination with metformin， in Chinese patients with type 2 diabetes： a 26?week， open?label， randomized， active comparator clinical trial［J］. Diabetes Obes Metab， 2016， 18（8）：803?811. doi:10.1111/dom.12674
27 RUSSELL-JONES D， VAAG A， SCHMITZ O， et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus （LEAD?5 met+SU）： a randomised controlled trial ［J］. Diabetologia， 2009， 52（10）：2046?2055. doi:10.1007/s00125-009-1472-y
28 GUNAJ R， RLLIN B， NHR J，et al. The glp-1 analogs liraglutide and semaglutide reduce atherosclerosis in apoe / and ldlr / mice by a mechanism that includes inflammatory pathways［J］，JACC Basic Transl Sci，2018，3（6）：844-857. doi:10.1016/j.jacbts.2018.09.004
29 YUE W， QU D， YANG Q.The GLP1 Receptor Agonist Liraglutide Protects Against Oxidized LDL-Induced Endothelial Inflammation and Dysfunction via KLF2.［J］.Iubmb Life， 2019， 71（9）：1347-1354. doi:10.1002/iub.2046
30 BURGMAIER M， LIBERMAN A， MLLMANN J， et al. Glucagon-like peptide-1 （GLP-1） and its split products GLP-1（9-37） and GLP-1（28-37） stabilize atherosclerotic lesions in apoe/ mice - ScienceDirect［J］. Atherosclerosis， 2013， 231（ 2）：427-435. doi:10.1016/j.atherosclerosis.2013.08.033
31 DI B， LI H W， LI W， et al. Corrigendum to "Liraglutide inhibited AGEs induced coronary smooth muscle cell phenotypic transition through inhibiting the NF-κB signal pathway" ［J］. Peptides， 2019，112：125-132. doi:10.1016/j.peptides.2018.11.008
32 BARALE C， BURACCO S， CAVALOT F， et al. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation ［J］. Thromb Haemost，2017，117（6）：1115-1128. doi:10.1160/th16-07-0586
33 XIA J， LI Q， LIU Y， et al. A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine［J］. Front Pharmacol， 2020，26（11）：372-380.
34 LEITER L A， BAIN S C， HRAMIAK I，et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes： a post hoc analysis of gender， age， and baseline CV risk profile in the SUSTAIN 6 trial［J］. Cardiovasc Diabetol， 2019，18（1）：73-84. doi:10.1186/s12933-019-0871-8
Options
Outlines

/

〈 〉